179 results on '"Kachergus, Jennifer M."'
Search Results
2. Rejuvenation of the aged brain immune cell landscape in mice through p16-positive senescent cell clearance
3. Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
4. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
5. Table S2 from Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
6. Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria
7. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers
8. Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria.
9. Abstract 1000: Associations of parity and body mass index with NanoString digital spatial protein profiling in early onset breast cancer
10. The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
11. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
12. First neuropathological description of a patient with Parkinson’s disease and LRRK2 p.N1437H mutation
13. Abstract 2203: Towards prediction of breast cancer risk in benign biopsies with high-plex GeoMx spatial protein profiling
14. Additional file 1 of Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
15. Glucocerebrosidase mutations in diffuse Lewy body disease
16. Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
17. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease
18. A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction
19. MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma
20. Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid
21. The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data
22. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
23. Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease
24. Lrrk2 pathogenic substitutions in Parkinson's disease
25. Abstract PS16-01: Intra-epithelial tumor immune landscapes are associated with clinical outcomes in early-stage triple-negative breast cancer
26. Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)
27. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
28. Abstract 1004: Quantitative digital spatial profiling reveals novel prognostic intratumoral immune signatures in triple-negative breast cancer
29. Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
30. Abstract PD5-06: Digital spatial mapping of the immune landscape of triple negative breast cancer reveals novel features of immune-tumor cell interaction
31. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinsonʼs disease
32. Association of α-, β-, and γ-Synuclein With Diffuse Lewy Body Disease
33. Expanding the clinical phenotype of SNCA duplication carriers
34. Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).
35. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
36. Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples
37. Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.
38. LRRK2 mutations and Parkinsonism
39. Abstract 3377: Simultaneous analysis of the mutational landscape and RNA and protein expression profile of HER2-positive breast cancer using 3D BiologyTM
40. EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population
41. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
42. Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors
43. Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
44. Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
45. Identification and targeting of M-phase progression downstream of HER2 in trastuzumab-sensitive and -resistant breast cancer cell lines.
46. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction
47. Gene Expression, Single Nucleotide Variant and Fusion Transcript Discovery in Archival Material from Breast Tumors
48. An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer
49. Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target.
50. Abstract 2005: Analysis of gene expression and copy number variation in breast tumors using both sequencing and hybridization-based platforms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.